Equities research analysts expect that argenx SE – (NASDAQ:ARGX) will post earnings per share of ($0.44) for the current quarter, Zacks reports. Three analysts have issued estimates for argenx’s earnings. The highest EPS estimate is $0.20 and the lowest is ($1.01). The firm is expected to announce its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that argenx will report full year earnings of ($2.93) per share for the current financial year, with EPS estimates ranging from ($3.57) to ($2.32). For the next financial year, analysts forecast that the firm will post earnings of ($4.93) per share, with EPS estimates ranging from ($6.03) to ($4.14). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for argenx.
Several brokerages recently issued reports on ARGX. Zacks Investment Research downgraded argenx from a “buy” rating to a “hold” rating in a research note on Wednesday. Wedbush increased their price objective on argenx from $131.00 to $144.00 and gave the stock an “outperform” rating in a research note on Friday, March 1st. Guggenheim began coverage on argenx in a research note on Friday, February 22nd. They set a “buy” rating and a $157.00 price target for the company. ValuEngine raised argenx from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Stifel Nicolaus reaffirmed a “buy” rating on shares of argenx in a research note on Monday, February 4th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $144.27.
argenx stock traded down $1.73 during mid-day trading on Thursday, hitting $128.63. The company’s stock had a trading volume of 92,444 shares, compared to its average volume of 149,421. The company has a market cap of $4.14 billion, a P/E ratio of -54.74 and a beta of 1.12. argenx has a 52-week low of $63.81 and a 52-week high of $135.58.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Story: What is a Buy-Side Analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.